Innovative RNAi Platform RXi Pharmaceuticals is focused on developing next-generation immuno-oncology therapeutics utilizing its proprietary self-delivering RNAi (sd-rxRNA) platform, presenting opportunities for collaborations or licensing agreements around advanced RNAi technology.

Academic and Industry Engagement The company's active participation in high-profile forums like Keystone Symposia and collaborations with institutions such as the Karolinska Institutet indicate a strong research network, which could facilitate partnership or joint development initiatives in cutting-edge RNA research.

Early Stage Revenue With revenues ranging from $1 million to $10 million and recent funding rounds, RXi is an emerging player, offering sales opportunities in specialized biotech manufacturing, research tools, or supporting clinical development phases.

Focused Therapeutic Area Specializing in immuno-oncology and T-cell/NK cell modulation, the company presents potential sales avenues with biotech firms, research labs, or service providers interested in immune cell therapies or RNA-based therapeutics.

Small but Growing Team Operating with a lean team of 11-50 employees, RXi is in a development phase emphasizing innovation and scientific advancement, indicating a strategic need for specialized services, outsourced R&D support, and technology solutions tailored for early-stage biotech companies.